A
Agenus
Our goal is to treat cancers with novel combinations using our unique portfolio of checkpoint antibodies, tumor microenvironment modifiers, vaccines & adjuvants
At a glance
- Founded
- 1994
- Headquarters
- Lexington, United States
- Listing
- IPO 2000
- Sector
- Biotech & Life Sciences
- Power Law
- Thoroughbred$100M+ revenue
Latest news
Press, funding announcements and product moves mentioning Agenus.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
- EPEW Healthcare Partners
- MCMentor Capital
Flagship Pioneering- GEGrazia Equity
- BVBCM Ventures
- ASAdvent Life Sciences
Source: Dealroom Talent Intelligence.
Alumni founders
Former Agenus employees who went on to found companies, sorted by Dealroom signal score.
ENEnvetecEst. 2021
Peter ThorntonIreland
Robert SteinUnited States
ABAbcuroEst. 2015
Stefano GullàUnited States
TTTessera TherapeuticsEst. 2018
Noubar AfeyanUnited StatesGlobal footprint
team presence
across markets
Patents
84 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Agenus on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Agenus on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.